OM
VIRX

Opaleye Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Opaleye Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-258,556
Closed -$2.07M – 47
2021
Q3 		$2.07M Buy
258,556
+1,367
+0.5% +$13.5K 0.39% 38
2021
Q2 		$2.92M Buy
257,189
+153,589
+148% +$1.54M 0.48% 43
2021
Q1 		$958K Buy
+103,600
New +$1.08M 0.14% 56
2017
Q3 		– Sell
-10,857
Closed -$1.03M – 40
2017
Q2 		$1.03M Sell
10,857
-4,857
-31% -$558K 0.43% 39
2017
Q1 		$2.25M Buy
+15,714
New +$2.25M 1.12% 28

Other funds holding VIRX

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Opaleye Management's VIRX Position: Q4 2021 in Review

Opaleye Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 258,556 shares — an estimated $2.07M sold.

Opaleye Management first reported a position in VIRX in Q1 2017 and held it in 5 quarters. The position peaked at $2.92M in Q2 2021. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

  • Opaleye Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Opaleye Management sold 258,556 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2.07M.
  • Opaleye Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2017 and held it in 5 quarters.
  • Opaleye Management's Viracta Therapeutics, Inc. Common Stock position peaked at $2.92M in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.